By: Alexandra Gerlach, Associate Editor, Julia Ziegengeist, PharmD, BCOP From: pharmacytimes.com In an interview with Pharmacy Times,® Julia Ziegengeist, PharmD, BCOP, clinical pharmacist coordinator of solid tumor oncology at the Levine Cancer Institute, Atrium Health, discussed data from her presentation at the HOPA Annual Meeting 2025 about adjuvant and neoadjuvant treatment of early-stage human epidermal growth factor receptor 2-negative (HER2-) …
-
-
The Spirit of Easter for the Breast Cancer Community
-
Why Would You Dismiss Your Doctor’s Breast Cancer Treatment Recommendations?
-
The Digital Divide and Breast Cancer
-
Politics and the Breast Cancer Survivor
-
Peace of Mind in a Breast Cancer World
